N. O. Shurko, M. I. Voroniak, T. V. Danysh

DOI: http://dx.doi.org/10.30970/sbi.0801.330


To correct factor deficiency or prevent bleeding in patients with hemophilia A, the replacement therapy is carried out. This therapy involves administrating plasma or recombinant preparations of factor VIII. A variety of plasma- and recombinant-derived factor preparations are used for haemophilia treatment in Ukraine. Depending on purification level, the following types of plasma-derived concentrates are defined: intermediate purity products obtained through classic techniques of precipitation/adsorption, and high-purity concentrates purified through ion exchange or affinity chromatography. Since the late 1980s, recombinant factor drugs were brought into use in medical practice. They are synthesised by a genetically engineered Chinese hamster ovary cell line or baby hamster kidney. Recombinant factors are classified in generations according to the additional content of impurity human or animal proteins in a final product. The article provides an analysis of the main plasma-derived and recombinant factor VIII preparations registered in Ukraine. Basic properties, methods of preparation and methods of viral inactivation are described. The advantages and disadvantages of plasma-derived and recombinant products are generalized.


blood coagulation, plasma and recombinant concentrate of factor VIII, chromatography, viral safety


1. Державний реєстр лікарських засобів України. On-line версія на веб-сайті www.drlz.kiev.ua

2. Зубаиров Д.М. Молекулярные основы свертывания крови и тромбообразования. Казань: Фен, 2000. 364 с.

3. Патент на винахід № 94299, Україна, МПК С07 1/22, С07К 14/755. Спосіб очищення фактора VIII згортання. Шурко Н.О., Даниш Т.В., Новак В.Л. Заявка № 2906990; Заявл. 03.07.2009 р.; Опубл 26.04.2011, Бюл. № 8. від 26.04.2011 р.

4. Патент на изобретение № (11)2445947, Россия, МПК С2(13), А61К38/37, А61К35/16. Способ получения концентрата фактора VIII из плазмы крови человека. Воробьев А.И., Берковский А.Л., Юрьев А.С. Заявка № 2010116125/15; Заявл. 26.04.2010; Опубл. 10.11.2010.

5. Ямкин А.В., Стронин О.В., Никитина Л.Н. Способ получения и свойства препарата VIII фактора свертывания плазмы крови человека. Сибирский медицинский журнал, 2009; 2(2): 17–20.

6. Calizzani G., Profili S., Candura F. et al. The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Тransfus, 2013; 11(4): 46-76.

7. Chandra S., Groener A., Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb. Research, 2002; 105(5): 391-400.

8. Chtourou S., Porte P., Nogre M. A solvent/detergent treated and 15 nm filtered factor VIII: a new safety standard for pharma-derived coagulation factor concentrates. Vox Sang, 2007; 92 (4): 327-337.

9. De Waure C., Cadeddu C., Gualano M.-R. Gestione terapeutica dell'emofilia A. IJPH, 2011; 8(2): 17-30.

10. Iorio A., Halimeh S., Holzhauer S. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII сoncentrates: a systematic review. Thromb. Haemost, 2010; 8(6):1256-1265.

11. Josephson C.D., Abshire T. The new albumin free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement. Clin. Adv. Hematol. Oncol, 2004; 2(7): 441-446.

12. Kim In Seop, Yong Woon Choi. Dry-heat treatment process for enhancing viral safety of an antihemohpilic factor VIII concentrate preperated from human plasma. J. Microbiol. Biotechnol, 2008; 18(5): 997-1003.

13. Larsson P.-O. High-performance liquid affinity chromatography. Meth. Enzymol, 1984; 104: 213-223.

14. Mannucci P., Franchini M. Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Тransfus, 2013; 11 (4): 77-81.

15. Marcel P.W.M. Te Booy, Anita Faber, Jan Over, Boudewijn W. Konig. Large scale purification of factor VIII by affinity chromatography: optimization of process parameters. J. Chromatogr, 1990; 8(2): 103-114.

16. Morfini M., Coppola A., Franchini M., Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Тransfus, 2013; 11(4): 55-63.

17. Pat. 6953837US. Factor VIII/vWF complexes and compositions. M. Fischer, B. Schonberger, Thomas-Urban, K. Dorner, F. Eibl - Appl. N 10/003.621; Filed: 02.11. 2001; Publ. 11.10.2005.

18. Pat. 7166709US. Haemostatically active preparation containing vWF and method for the production thereof. Josic Stadler, Monika Gruber - Appl. N 10/257.375; Filed: April 04.04. 2001; Publ. 23.01.2007.

19. Pipe S.W. Recombinant clotting factor. Thromb. Haemost, 2008; 99(5): 840-850.


  • There are currently no refbacks.

Copyright (c) 2014 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.